Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE/HAIC + Lenvatinib + Sintilimab Neoadjuvant for HCC
NCT05250843Phase 3Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Recurrence-free Survival at 12 months. Status: unknown.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05250843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250843.